Company intelligence / Profile preview

Regor Therapeutics

Cambridge, Massachusetts, USAregor.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Regor has reported positive topline results from a Phase 2a study of its oral small molecule GLP‑1R agonist RGT‑075 for obesity and has initiated a Phase 2b trial. Its next-generation CDK inhibitor portfolio was acquired by Genentech/Roche for $850M up-front in late 2024. The company continues to advance additional preclinical and clinical candidates across metabolic disease, oncology, and immunology.

Therapeutic areas: OncologyImmunologyMetabolic Disorders
Modalities: Small moleculesOral therapeutics (notably GLP‑1R agonists)
Industry: Biotech

Drug pipeline

6 assets

RGT-075

5 more assets in the full pipeline.

Request access →

Partnerships

Roche/Genentech ($850M up-front deal on next-gen CDK inhibitors in late 2024)

Beyond the preview

Go deeper on Regor Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regor Therapeutics.

Explore the full profile